DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 1, 1997, Pages 59-69

  Goldberg, Michael R ^a   Lo, Man Wai ^b   Christ, David D ^b   Chiou, Rita ^b   Furtek, Christine I ^b   Amit, Ohad ^b   Carides, Alexandra ^b   Biollaz, Jerome ^b   Piguet, Valerie ^b   Nussberger, Juerg ^b   Brunner, Hans R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG METABOLITE; LOSARTAN; PLACEBO;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; HEART RATE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT;

ADULT; ANGIOTENSIN II; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES;

EID: 12644279881     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90182-X     Document Type: Article

References (20)

1. Christen Y, Waeber B, Nussberger J, Porchet M, Borland N, Lee R, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation 1991;83:1333-42.
2. Munafo A, Christen Y, Nussberger J, Shum L, Borland M, Lee R, et al. Drug concentration-response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
3. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans P. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992;32:135-65.
4. Goldberg M, Tanaka W, Barchowsky A, Bradstreet T, McCrea J, Lo MW, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13.
5. Goldberg M, Bradstreet T, McWilliams E, Tanaka W, Lipert S, Bjornsson T, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
6. 1-receptor antagonist. J Pharmacol Exp Ther 1991;259:861-70.
7. Chiu AT, Carini DJ, Duncia JV, Leung KH, McCall DE, Price WA, et al. DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists. Biochem Biophys Res Commun 1991;177:209-17.
8. Wong Y, Holm K, Burcham D, Huang SM, Quon C. The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. Biopharm Drug Dispos 1994;15:53-63.
9. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Non-peptide angiotensin II receptor antagonists; XI: pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255: 211-7.
10. Paraloi G, Casadei R, Groppelli A, Di Rienzo M, Mancia G. Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension 1989;13:647-55.
11. Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK-954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995;35:515-20.
12. Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK-954) in the dog. J Pharmacol Exp Ther 1994;268:1199-205.
13. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992;573:295-301.
14. Chiou R, Lo MW. High-performance liquid Chromatographic determination of angiotensin II receptor antagonists in human plasma and urine; I: DuP 532 (L-694,492). J Chromatogr 1992;581:165-70.
15. Nussberger J, Fasanella D'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987;9:39-44.
16. Nussberger J, Keller J, Waeber B, Brunner HR. Angiotensin II measurement with high-affinity monoclonal of antibodies. J Hypertension 1988;6(suppl 4):424-5.
17. Cochan WA, Cox GM. Experimental design. New York: John Wiley, 1957;127-39.
18. Merck & Co. Cozaar (losartan potassium tablets). In: Physician's desk reference. 50th ed. Montvale, NJ: Medical Economics, 1996:1628-30.
19. Wong PC, Christ DD, Wong YN, Lam GN. Nonpeptide angiotensin II receptor antagonists: pharrnacokinetics and pharmacodynamics of EXP3174, an active metabolite of losartan, in rats. Pharmacology 1996;52:25-9.
20. Beauchamp H, Chang R, Siegl P, Gibson R. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J Pharmacol Exp Ther 1995;272:612-8.